In This Article:
Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies with strong innovation potential and solid financial health that can capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 24.13% | 24.28% | ★★★★★★ |
| Ardelyx | 25.47% | 69.63% | ★★★★★★ |
| Sarepta Therapeutics | 24.09% | 42.97% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.34% | 70.30% | ★★★★★★ |
| Clene | 77.61% | 59.19% | ★★★★★★ |
| TG Therapeutics | 34.86% | 56.98% | ★★★★★★ |
| Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
| Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Madrigal Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for non-alcoholic steatohepatitis (NASH) in the United States, with a market cap of $6.80 billion.
Operations: Madrigal focuses on developing treatments for non-alcoholic steatohepatitis (NASH) in the U.S. As a clinical-stage company, it currently does not report revenue from product sales.
Madrigal Pharmaceuticals has been actively engaging the healthcare community, evidenced by their recent presentations at multiple high-profile conferences. Despite reporting a widening net loss of $106.96 million in Q3 2024, up from $98.74 million year-over-year, they have shown a commitment to innovation through significant R&D investments and the progression of their MAESTRO-NASH OUTCOMES trial. This focus on developing treatments for NASH cirrhosis positions them uniquely within the biotech sector, where they anticipate revenue growth at an impressive rate of 56% per year, outpacing the US market average significantly.
-
Take a closer look at Madrigal Pharmaceuticals' potential here in our health report.
-
Evaluate Madrigal Pharmaceuticals' historical performance by accessing our past performance report.
Corning
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Corning Incorporated operates in the display technologies, optical communications, environmental technologies, specialty materials, and life sciences sectors globally and has a market capitalization of approximately $41.01 billion.
Operations: Corning generates revenue from multiple segments, with optical communications and display technologies being the largest contributors at $4.19 billion and $3.77 billion, respectively. Specialty materials and environmental technologies also play significant roles in its revenue model. The company operates across various sectors both in the United States and internationally, reflecting a diverse business portfolio.